A Study of GC3107(BCG Vaccine) in Healthy Infants
Conditions:   BCG Vaccination Reaction;   Tuberculosis Interventions:   Biological: GC3107;   Biological: Intradermal BCG SSI inj. Sponsor:   Green Cross Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Azacytidine During Anti-tuberculosis Therapy
Condition:   Tuberculosis, Pulmonary Interventions:   Drug: Azacitidine Injection [Vidaza] - Phase A Group;   Drug: Azacitidine Injection [Vidaza] - Phase B Group;   Drug: Azacitidine Injection [Vidaza] - Phase C Group;   Drug: Azacitidine Injection [Vidaza] - Phase D Group Sponsors:   Andrew Dinardo;   Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Condition:   Multidrug Resistant Tuberculosis Interventions:   Drug: Bedaquiline;   Drug: Pretomanid;   Drug: Moxifloxacin;   Drug: Linezolid;   Drug: Clofazimine;   Drug: Directly observed therapy (DOT) Sponsors:   Medecins Sans Frontieres, Netherlands;   University of Sussex;   London School of Hygiene and Tropical Medicine;   Doris Goodwin Hospitals, Kwazulu Natal, South Africa;   Don McKenzie Hospitals, Kwazulu Natal, South Africa;   Republican Sc...
Source: ClinicalTrials.gov - May 8, 2019 Category: Research Source Type: clinical trials

Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
Conditions:   Tuberculosis;   Latent Tuberculosis;   HIV/AIDS Interventions:   Other: Streamlined weekly DOT visits;   Other: Weekly DOT visit reminders;   Other: Cost reimbursement DOT;   Other: 99DOTS;   Other: Weekly SAT dosing reminders/check-ins;   Other: Cost reimbursement SAT Sponsors:   University of California, San Francisco;   Makerere University;   Johns Hopkins Bloomberg School of Public Health; &nbs...
Source: ClinicalTrials.gov - May 2, 2019 Category: Research Source Type: clinical trials

A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
Conditions:   Pulmonary Disease;   Pulmonary Infection;   Non-Tuberculous Mycobacterial Pneumonia Intervention:   Sponsors:   Seoul National University Hospital;   Asan Medical Center;   Samsung Medical Center;   Pusan National University Hospital;   Severance Hospital;   Pusan National University Yangsan Hospital;   Chonnam National University Hospital;   Korean Institute of Tuberculosis;   International Tuberculosis Research...
Source: ClinicalTrials.gov - May 1, 2019 Category: Research Source Type: clinical trials